Last updated on April 2018

Study of LM11A-31-BHS in Mild-moderate AD Patients

Brief description of study

The purpose of this study is to determine the safety of 2 doses of LM11A-31-BHS in 180 patients with Alzheimer's Disease versus placebo and to access biomarker and clinical exploratory endpoints of LM11A-31-BHS

Detailed Study Description

The goal of this AD Pilot is to conduct a prospective, double-blind, multicenter, phase IIa exploratory safety, feasibility and proof-of-concept trial in mild to moderate Alzheimer's disease patients with the orally bioavailable p75 neurotrophin receptor ligand LM11A-31-BHS dosed twice daily for 26 weeks. Successful completion of this trial will provide the safety, endpoint and statistical basis for the design and execution of a phase 2b/3 efficacy trial. It will also bring to the AD field a much-needed new set of target mechanisms and will help pioneer the strategy of the concomitant targeting of multiple fundamental AD-related pathological processes.

During the 26 weeks study period the eligible patients will be invited to 5 visits.

Safety monitoring will include the full extent of phase 2 clinical, electrophysiological and laboratory testing.

Clinical Study Identifier: NCT03069014

Contact Investigators or Research Sites near you

Start Over

Reinhold Schmidt, Prof. Dr.

University Hospital Graz
Graz, Austria
  Connect »

Douglas Imarhiagbe, OA Dr. med.

Landeskrankenhaus Hall
Hall in Tirol, Austria
  Connect »

Jakub Hort, Prof. MD

Charles University
Praha, Czech Republic
  Connect »

Katerina Sheardová, MD

Neurology Clinic of Martin Urbanek
Brno, Czech Republic
  Connect »

Ladislav Pazdera, MD

Vestra clinics s.r.o
Rychnov nad Kneznou, Czech Republic
  Connect »

Martin Valis, MD

Chocen, Czech Republic
  Connect »

Joachim Springub, Dr. med.

Studienzentrum Nordwest
Westerstede, Germany
  Connect »

Peter Schönknecht, Prof. Dr.

S chsisches Krankenhaus Arnsdorf
Arnsdorf, Germany
  Connect »

Ralf Bodenschatz, Dipl.-med.

Pharmakologisches Studienzentrum Chemnitz GmbH
Chemnitz, Germany
  Connect »

Oliver Peters, Doz. Dr.

Charit Universit tsmedizin Berlin
Berlin, Germany
  Connect »

Niels Andreasen, Prof.Dr.

Karolinska University
Stockholm, Sweden
  Connect »

Pawel Kermer,

Nordwestkrankenhaus Sanderbusch
Sande, Germany
  Connect »

Irma Schöll, MD

Zentrum f r klinische Forschung
Bad Homburg, Germany
  Connect »

Daniel Bittner, MD

Universit tsklinik Magdeburg, Klinik f r Neurologie
Magdeburg, Germany
  Connect »

Andrej Pauls, Dipl.Psy.MD

Neurologie Sendlinger Strasse Studien- und Ged chtniszentrum M nchen
München, Germany
  Connect »

Robert Perneczky, Prof. MD

LMU M nchen Klinik f r Psychiatrie und Psychotherapie
München, Germany
  Connect »

Mercé Boada Rovira, MD

Fundaci ACE
Barcelona, Spain
  Connect »

Rafael Blesa González, MD

Fundaci n de Gesti n Sanitaria del Hospital de la Santa Creu I Sant Pau, C
Barcelona, Spain
  Connect »

Raquel Sánchez del Valle, MD

Hospital Cl nic de Barcelona
Barcelona, Spain
  Connect »

Ana Frank García, Prof. MD.

Hospital la Paz
Madrid, Spain
  Connect »

Emilio Franco Macías, MD

Hospital Virgen del Roc o
Sevilla, Spain
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.